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abstract
The EORTC Lung Cancer Group (LCG) maintains a multidisciplinary clinical
trial portfolio. Over the years research has moved from investigators’ ideas,
to pharmacological company driven studies of new drugs, to the more recent
biological marker driven studies. Non-small cell lung cancer (NSCLC) is the most
common malignancy and has been the area of greatest activity. Malignant pleural
mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis which has
been a surprising area of collaborative research in the LCG for many years. Small cell
lung cancer (SCLC) is well named, as it has become ‘small’ in every way, and has
changed from being the most hopeful of tumors to what has now become a trialist’s
despair. This review will provide a review of major clinical trials and the contribution
of the LCG. Challenges and priorities in the way forward will be presented and
discussed.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Non-small cell lung cancer
Many things have changed in the history of non-
small cell lung cancer (NSCLC) over the past 50 years.
Much of it has been summarized in the special issue
of the European Journal of Cancer commemorating the
40-year anniversary of the EORTC, 1 and therefore we
concentrate here on the past ten years in detail. We are
still faced with only about 10% of patients having curative
resection, and only about 20% having treatment with
radical intent. Both of these areas have been important
to the EORTC Lung Cancer Group (LCG) and involve
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a multidisciplinary approach to management − which
is progress in itself. The LCG has been involved in
neoadjuvant and adjuvant studies and has collaborated
with other European trial groups. This has brought us to
the established role of adjuvant therapy, the acceptance
of neoadjuvant treatment, and the development of
presurgery as a ‘window’ for testing new treatments.
Stage III disease was the area of a major innovative
trial which allowed us a number of investigational
opportunities. In EORTC trial 08958, a number of different
chemotherapy regimens were used pre-radical local
therapy and have all been published. 2 In EORTC trial
08941 randomization was done after chemotherapy and
the trial compared radical surgery to radical radiotherapy,
showing that the two treatment options were equivalent
1359-6349 © 2012 European Organisation for Research and Treatment of Cancer.
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Table 1 – EORTC phase II trials in mesothelioma
EORTC
Trial
Year
activated
Patients Chemotherapy Response
rate (%)
Median OS
(days)
Median PFS
(days)
08976 1998 30 Temozolomide 13 4 196 116
08966 1997 25 Caelyx 14 7 367 167
08943 1995 25 Gemcitabine 15 7 240 162
08924 1993 14 Paclitaxel 16 0 273 98
08901a 1992 14 Etoposide 17 7
5
243
206
107
101
08864 1986 14 Epirubicin 18 13 276 144
08852 1984 46 Mitoxantrone 19 3 237 124
08992 1999 24 Raltitrexed 20 25 213 192
a Two phase II trials.
but had different toxicity spectrums. 3 The unanswered
question now is if three modalities are better than two.
However, most lung cancer is advanced, and treatment
is palliative, and the most frequently used palliative
regimen worldwide is carboplatin and paclitaxel. This
regimen was the investigational arm of a phase III study
at the EORTC with comparison to the then standard of
cisplatin and tenioposide, and these data were used for
the registration of this combination. 4 Since then much
work has been done on the number of cycles, the role
of maintenance therapy, and the deﬁnition of subgroups
with mutations which predict both a better prognosis
and a different treatment pathway. The LCG is currently
conducting a switch maintenance study, EORTC 08092,
with pazopanib and actively looking at the role of radical
treatment in subgroups with mutations.
2. Malignant mesothelioma
The etiology, epidemiology, diagnosis, prognosis and
management of malignant pleural mesothelioma (MPM)
have recently been reviewed and guidelines have been is-
sued. 5 Essential prognostic factors associated with better
outcome are earlier stage and epithelioid histologic type
as described by the LCG and other groups. 6 Additional
bad prognostic factors are the presence of symptoms,
poor performance status, advanced age, male gender,
elevated white blood cell count (WCC) and platelets, and
weight loss. The prognostic value of asbestos exposure is
not proven.
Radical surgery in MPM remains controversial. Op-
erative mortality has fallen to an acceptable level of
around 5% in experienced centers, but morbidity remains
high at around 50%. 7,8 In the EORTC phase II trial
08031, administration of three modalities (chemotherapy,
surgery, and radiotherapy) was only possible in 42% of
patients within the proposed ideal time of 90 days. The
median survival was 33 months in the 37 patients receiv-
ing tri-modality treatment. 9 Although the multimodality
treatment procedure seems feasible, overall treatment
time is long, and psychological distress is considerable.
These ﬁndings stress the importance of and the need for
a large prospective multicenter trial in which operable
patients with early-stage resectable MPM are randomly
assigned to a surgical and a non-surgical management. 10
The feasibility of this approach has been explored in
the UK MARS trial in which the randomization was
between extrapleural pneumonectomy (EPP) followed by
post-operative radiotherapy (PORT) and any palliative
treatment, including pleurodesis, following an induction
treatment with chemotherapy for all patients. The
results of the feasibility part of this trial have recently
been released and show no difference in survival
between treatment arms 11,12 thereby questioning the
appropriateness of EPP as surgical approach in MPM.
Further trials in this disease are necessary and remain
on the LCG agenda.
Although rare cases of complete response have
been reported with systemic chemotherapy, the aim
of chemotherapy is primarily palliation, and unlike
surgical cases, few anecdotes are present in the literature
(although many oncologists have seen impressive
durable responses). In the past decades many phase II
studies have been performed to select drugs with a
potential activity against MPM, and Table 1 summarizes
the EORTC experience. 13−20 A three-arm randomized
phase III study was initiated in the United Kingdom that
compared the efﬁcacy of two different chemotherapy
regimens, one low-dose platinum combination and one
single-agent third generation drug, with best supportive
care. 21 The study was prematurely stopped due to slow
accrual and was hence insufﬁciently powered to show a
survival difference even after pooling the results of both
chemotherapy arms. However, a positive trend favoring
the vinorelbine single-agent treatment was observed.
Still, the choice of the comparative chemotherapy is not
considered optimal.
The promising results obtained in previous phase I
and II trials with raltitrexed led to a phase III trial,
EORTC 08983, conducted by the LCG designed to
determine whether ﬁrst-line treatment with raltitrexed,
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a thymidine synthase inhibitor, and cisplatin results
in superior outcome compared with cisplatin alone in
patients with MPM. 22 Patients with histologically proven
advanced MPM, chemo-naive, WHO performance status
0 to 2, and adequate hematological, renal, and hepatic
function were randomly assigned to receive cisplatin
(80mg/m2 IV) on Day 1, either as single agent or
combined with raltitrexed (3mg/m2).
Two hundred ﬁfty patients were randomized. There
were no toxic deaths, and the main grade 3 or 4 toxicities
observed were neutropenia and emesis which were
reported twice as often in the combination arm. Among
213 patients with measurable disease, response rate was
13.6% with cisplatin versus 23.6% for the combination
(P=0.056). No difference in health-related quality of life
(HRQOL) was observed on any of the scales. However,
it is clear that both groups had impairment of global
HRQOL scores, when compared to a normative general
population. Importantly, in this disease population, this
level did not deteriorate, remaining stable over treatment
time.
Median overall survival was 8.8 months for cisplatin
(95% conﬁdence interval [CI] 7.8–10.8) versus 11.4 months
(95%CI 10.1−15) for the combination, and 1-year survival
was 40% versus 46%, respectively (P=0.048). Based on
these results it can be concluded that the combination
of raltitrexed and cisplatin improves overall survival (OS)
and is superior compared to cisplatin alone without
harmful effect on HRQOL. These results are comparable
to the results obtained in the other randomized phase III
EMPHACIS-trial of cisplatin alone versus cisplatin com-
bined with pemetrexed in patients with MPM conducted
around the same time. 23 Although the signiﬁcance level
in the EORTC raltitrexed study is somewhat less than
in the EMPHACIS-trial, this could be the result of its
lower sample size. The magnitude of the observed
improvement in the combination arms − as expressed
by the hazard ratio − and the outcome in both control
arms are similar, making these trials comparable and
conﬁrmatory of each other. This equipoise is conﬁrmed
by an adjusted indirect comparison of response rate
(odds ratio [OR] 0.56, 95%CI 0.24–1.30), progression-free
survival (PFS) (OR 1.15, 95%CI 0.82–1.61) and OS (OR 0.99,
95%CI 0.69–1.41).The cost-effectiveness analysis found
raltitrexed plus cisplatin to be cost-effective at a cost per
quality adjusted life year of £11,425 compared to cisplatin
and £25,331 compared to Active Supportive Care. 24 These
data have led to the recent registration of raltitrexed
for the treatment of MPM in several European countries.
Based on these two randomized phase III trials, it is now
generally accepted to treat patients with MPM with a
combination of an antifolate with platinum.
Recent pharmaceutical developments have focused
on the identiﬁcation and inhibition of molecular
pathways involved in the growth and progression
of MPM. A number of novel agents have been or
are being evaluated including drugs targeted against
epidermal growth factor, platelet-derived growth factor,
vascular endothelial growth factor, src kinase, histone
deacetylase, proteosome, and mesothelin. 25−27 Of these
approaches, thalidomide is negative. 28 Bevacuzimab is
still being tested with a platinum pemetrexed combi-
nation using a biomarker generated from the previous
bevacuzimab study. 29,30 Sorafenib appears interesting
and more data will be available soon. 31,32 Bortezomib
appears very active and is the current focus of the LCG
with a program of tissue collection, EORTC trial 08052, to
look at biological pathways involved in drug resistance to
this and other agents. 33 A randomized second-line trial
is comparing best standard of care with and without a
new molecular NGR-hTNF which should deliver tumor
necrosis factor via targeting vessels. 34 The LCG is proud
to have been able to harness interest from many centers
in many countries to recruit patients with this rare
disease.
3. Small cell lung cancer
The backbone of treatment for small cell lung cancer
(SCLC) is chemotherapy. Standard treatments remain
platinum- or anthracycline-based and have changed
little over the past ten years. The most recent ﬁrst-
line contender has been amrubicin, a third generation
synthetic anthracycline agent which does not appear
to cause anthracycline-related cardiomyopathy. It has
shown comparable response rate as a single agent (61%)
to cisplatin/etoposide (63%) and a promising response
of 77% in combination with cisplatin (EORTC trial
08062). 35 Toxicity was largely myelosuppression in all
three arms. New combinations in SCLC must show a
survival advantage over cisplatin/etoposide unless there
is a signiﬁcantly different toxicity proﬁle.
Sunitinib, a multi-targeted inhibitor of VEGFR-1/2/3,
PDGFR alpha/beta, Flt 3, c-kit, and RET, has been
developed as monotherapy in second-line treatment for
relapsed or refractory SCLC. Sunitinib has anecdotally
given responses in this EORTC second-line study, EORTC
trial 08061, which have been conﬁrmed by PET scanning.
This trial was slow to recruit, is complex in design, and
challenges future design of this type of study within a
cooperative group.
Brain metastases are frequent in SCLC and are
associated with serious impairment in quality of life
and shortened survival. The EORTC has led the way
in the prevention of brain metastasis with results
that have made a real impact on the management of
SCLC and have prolonged survival. Two clinical trials
evaluating prophylactic cranial irradiation (PCI) have
been conducted by the LCG and the EORTC Radiation
Oncology Group in the last decade (EORTC trials 22003–
08004 and 22993–08993). The impact of PCI on the
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incidence of brain metastasis, OS, and quality of life was
evaluated.
EORTC trial 22993/08993 is the only study ever
conducted to establish the role of PCI in stage IV SCLC
(or extensive-stage SCLC). Historically, in stage IV SCLC
radiotherapy has always had a role in the palliation
of symptoms but no proven impact on survival. This
EORTC-led study compared PCI to no further therapy
in 286 patients who had responded to chemotherapy. 36
The most common regimen prescribed was 20Gy in
5 fractions followed by 30Gy in 10 fractions. PCI resulted
in a signiﬁcant reduction in the risk of symptomatic
brain metastases (HR 0.27, 95%CI 0.16–0.44; p< 0.001)
and doubled the one-year survival (27.1%, 95%CI 19.4–
35.5 in the PCI group and 13.3%, 95%CI 8.1–19.9 in the
control group). The quality of life analysis of the study
showed that the irradiated group had more prolonged
hair loss and increased fatigue. 37 The mean global health
status score was 8 points higher in the PCI group at
6 weeks (p=0.018) and 3 months (p=0.056). However,
these observed differences were below the cut-off of a
10-point difference for clinical signiﬁcance. As a result of
this study, PCI was rapidly adopted internationally as a
new standard treatment.
The second study, EORTC trial 22003–08004, in stage
I−III SCLC (or limited-stage SCLC), addressed the question
of the standard dose of prophylactic radiation to be
delivered to the brain. 38 A meta-analysis demonstrated a
signiﬁcant reduction in brain metastasis and an improve-
ment in OS with PCI 39 and suggested that higher doses of
PCI may be associated with a reduction in the incidence
of brain metastases. In this intergroup study (Intergroupe
Francophone de Cance´rologie Thoracique and EORTC)
720 patients with stage I−III SCLC in complete remission
after chemotherapy and thoracic radiotherapy were
randomly assigned to a standard (25Gy) or higher (36Gy)
PCI total dose delivered using either conventional or
accelerated hyperfractionated radiotherapy. There was
no signiﬁcant difference in the two-year incidence
of brain metastases between the standard-dose group
and the higher-dose group, 29% and 23%, respectively
(HR 0.80, 95%CI 0.57–1.11; p= 0.18). Moreover, mortality
was increased in the high-dose group, with two-year OS
of 42% and 37% respectively (HR 1.20, 95%CI 1.00–1.44;
p= 0.05). The excess in mortality remains unexplained,
as there was no excess of treatment-related deaths in
this group. Long-term follow up revealed no signiﬁcant
difference between the two groups in any of the 17
selected items assessing quality of life, neurological, and
cognitive functions. In both groups a mild deterioration
across time of communication deﬁcit, weakness of
legs, intellectual deﬁcit, and memory was observed
(all p< 0.005). 40 The standard dose of PCI (25Gy in
10 fractions) therefore remains the standard of care in
stage I−III SCLC patients.
4. Conclusion
With the development of personalized medicine, there
has never been a better time for the LCG to break
down country barriers and develop research strategies
to answer difﬁcult clinical questions while studying the
biology of lung cancer in all its forms. This is the
challenge, and with support from colleagues in other
EORTC Groups and the staff at EORTC Headquarters, we
can respond to this challenge.
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